Zevin Asset Management LLC Sells 404 Shares of Eli Lilly and Company $LLY

Zevin Asset Management LLC cut its position in Eli Lilly and Company (NYSE:LLY) by 3.2% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 12,131 shares of the company’s stock after selling 404 shares during the period. Zevin Asset Management LLC’s holdings in Eli Lilly and Company were worth $9,456,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also bought and sold shares of the company. Bryn Mawr Trust Advisors LLC grew its position in shares of Eli Lilly and Company by 1.0% during the second quarter. Bryn Mawr Trust Advisors LLC now owns 5,233 shares of the company’s stock worth $4,079,000 after purchasing an additional 52 shares in the last quarter. Paulson Wealth Management Inc. lifted its holdings in shares of Eli Lilly and Company by 17.4% in the second quarter. Paulson Wealth Management Inc. now owns 1,125 shares of the company’s stock worth $877,000 after buying an additional 167 shares in the last quarter. Sustainable Insight Capital Management LLC grew its stake in Eli Lilly and Company by 37.5% during the second quarter. Sustainable Insight Capital Management LLC now owns 12,884 shares of the company’s stock valued at $10,043,000 after acquiring an additional 3,517 shares in the last quarter. Savant Capital LLC increased its holdings in Eli Lilly and Company by 3.6% in the 2nd quarter. Savant Capital LLC now owns 53,587 shares of the company’s stock valued at $41,773,000 after acquiring an additional 1,857 shares during the last quarter. Finally, Malaga Cove Capital LLC purchased a new stake in Eli Lilly and Company in the 2nd quarter worth $282,000. 82.53% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities analysts have weighed in on LLY shares. Sanford C. Bernstein restated an “outperform” rating on shares of Eli Lilly and Company in a report on Monday. Leerink Partnrs lowered shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 7th. Erste Group Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Tuesday, October 14th. Daiwa Capital Markets cut shares of Eli Lilly and Company from an “outperform” rating to a “neutral” rating and set a $700.00 price objective for the company. in a research note on Sunday, August 17th. Finally, Daiwa America cut shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Sunday, August 17th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and eight have issued a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $950.00.

Insider Buying and Selling

In related news, CEO David A. Ricks acquired 1,632 shares of the company’s stock in a transaction that occurred on Tuesday, August 12th. The shares were bought at an average price of $644.77 per share, with a total value of $1,052,264.64. Following the completion of the transaction, the chief executive officer directly owned 546,601 shares in the company, valued at $352,431,926.77. This trade represents a 0.30% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Gabrielle Sulzberger acquired 117 shares of the business’s stock in a transaction dated Tuesday, August 12th. The stock was purchased at an average cost of $641.18 per share, for a total transaction of $75,018.06. Following the transaction, the director owned 2,703 shares in the company, valued at approximately $1,733,109.54. The trade was a 4.52% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last 90 days, insiders have acquired 4,314 shares of company stock valued at $2,766,929. 0.14% of the stock is owned by insiders.

Eli Lilly and Company Trading Down 1.3%

NYSE LLY opened at $924.80 on Friday. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $955.46. The company’s 50-day moving average price is $796.15 and its 200-day moving average price is $775.03. The stock has a market cap of $874.29 billion, a PE ratio of 60.52, a PEG ratio of 1.21 and a beta of 0.43. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, beating the consensus estimate of $6.42 by $0.60. The firm had revenue of $17.60 billion during the quarter, compared to the consensus estimate of $16.09 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company’s revenue was up 53.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Equities research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, December 10th. Shareholders of record on Friday, November 14th will be issued a dividend of $1.50 per share. The ex-dividend date is Friday, November 14th. This represents a $6.00 dividend on an annualized basis and a yield of 0.6%. Eli Lilly and Company’s dividend payout ratio is currently 29.35%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.